AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1. (currently amended): A pharmaceutical composition comprising an epothilone together with a pharmaceutically acceptable carrier comprising 10 to 62.5 % v/v water, 12.5 to 65 % v/v ethanol, and 10 to 25 % v/v polyoxyethylene sorbitan monooleate, wherein the composition comprises at least one cyclodextrin, and wherein the epothilone is provided ~~in a therapeutically acceptable concentration~~ at a dosage level between about 1 mg/m^2 and about 200 mg/m^2 ~~upon administration to a patient~~.

2-3. (canceled)

4. (previously presented): The pharmaceutical composition of Claim 1, wherein the cyclodextrin is selected from the group consisting of β-cyclodextrin, hydroxypropyl-β-cyclodextrin, and sulfopropyl-β-cyclodextrin.

5. (original): The pharmaceutical composition of Claim 4, wherein the epothilone is selected from the group consisting of epothilone D, epothilone B, 9,10-dehydro-epothilone D, and 9,10-dehydro-epothilone B.

6. (original): The pharmaceutical composition of Claim 5, wherein the epothilone is epothilone D.

7. (original): The pharmaceutical composition of Claim 6, wherein the cyclodextrin is hydroxypropyl-β-cyclodextrin.

8. (original): The pharmaceutical composition of Claim 6, wherein the cyclodextrin is sulfopropyl-β-cyclodextrin.

9-14. (canceled)

15. (currently amended): A method of preparing a pharmaceutical composition, said method comprising the steps of

obtaining a lyophilate comprising an epothilone and a cyclodextrin; and

dissolving said lyophilate in a [[suitable]] reconstitution solvent comprising 10 to 62.5 % v/v water, 12.5 to 65 % v/v ethanol, and 10 to 25 % v/v polyoxyethylene sorbitan monooleate.

16. (currently amended): The method of Claim 15, wherein the reconstitution solvent comprises ~~one or more of an alcohol and a glycol~~ between about 15 and about 20 % v/v polyoxyethylene sorbitan monooleate.

17-21. (canceled)

22. (original): A soft gel cap comprising a pharmaceutical composition of Claim 1.

23. (new): The pharmaceutical composition of Claim 1, wherein the epothilone is provided at a dosage level between about 10 mg/m^2 and about 150 mg/m^2.

24. (new): The pharmaceutical composition of Claim 1, wherein the epothilone is provided at a dosage level between about 15 mg/m^2 and about 50 mg/m^2.